LIXT Insider Trading Activity and SEC Form 4 Filings
LIXT insider trading summary
No open-market insider purchases or sales of Lixte Biotechnology Holdings, Inc. (LIXT) have been reported on SEC Form 4 in the past 12 months.
Latest LIXT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 3, 2023 | Rene Bernards | Director | Buy | $14K (5,527 @ $2.51) |
| Oct 3, 2023 | der Baan Bastiaan Jeroen van | President and CEO | Buy | $28K (10,000 @ $2.80) |
| Oct 2, 2023 | Rene Bernards | Director | Buy | $10K (4,473 @ $2.29) |
| Dec 30, 2022 | der Baan Bastiaan Jeroen van | Director | Buy | $49K (10,000 @ $4.90) |
| Dec 15, 2022 | Rene Bernards | Director | Buy | $8K (15,000 @ $0.51) |
| Dec 12, 2022 | Rene Bernards | Director | Buy | $6K (10,000 @ $0.61) |
| Dec 9, 2022 | Eric Forman | Vice President and COO | Buy | $3K (5,000 @ $0.63) |
| Dec 9, 2022 | Eric Forman | Vice President and COO | Buy | $6K (10,000 @ $0.60) |
| Dec 9, 2022 | Eric Forman | Vice President and COO | Buy | $701 (1,112 @ $0.63) |
| Nov 22, 2022 | Eric Forman | Vice President and COO | Buy | $1K (2,484 @ $0.56) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.